https://cdantigens.com/index.p....hp/understanding-beh
We undertook a retrospective analysis of data from patients at a single institution who received a diagnosis of novel non-muscle-invasive bladder cancer (NMIBC) and underwent transurethral resection of bladder tumor (TURBT) between 2017 and 2022. Various demographic and comorbidity factors, in addition to tumor recurrence, progression, stage, and grade, were used to analyze BCG immunization status. After careful
Like
Comment
Share
